the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
In May 2022, we entered into a loan and security agreement (the Loan Agreement) with SVB Innovative Credit Growth Fund IX, LP and Innovative Credit Growth Fund VIII-A, LP pursuant to which we were ab…
royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized under the Novartis Agreement in the three months ended March 31, 2026 and 2025. Duri…
Reciprocal relationship from NVSEF graph: Reciprocal relationship from BIOA graph: royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized u…
BioAge Labs, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BIOA-DEBT-8200
Warrants outstanding: 214000
90%
xbrl warrant detail from xbrl 2025-12-31.
BIOA-DEBT
Debt stack $4.0M
90%
Market cache reports total debt of $4.0M.
BIOA-DEBT-8201
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
BioAge Labs, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioAge Labs, Inc..
BioAge Labs, Inc. Ownership
Holder
Name
Confidence
Evidence
BIOA-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 146 tracked holders.
